Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 7411 results found since Jan 2013.
Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions
World Psychiatry. 2023 Oct;22(3):394-412. doi: 10.1002/wps.21120.ABSTRACTTreatment-resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision-making and health outcomes does not currently exist. Instead, a plethora of definitions have been proposed, which vary significantly in their conceptual framework. The absence of a consensus definition hampers precise estimates of the prevalence of TRD, and also belies efforts to identify risk factors, prevention opportunities, and effective inte...
Source: World Psychiatry - September 15, 2023 Category: Psychiatry Authors: Roger S McIntyre Mohammad Alsuwaidan Bernhard T Baune Michael Berk Koen Demyttenaere Joseph F Goldberg Philip Gorwood Roger Ho Siegfried Kasper Sidney H Kennedy Josefina Ly-Uson Rodrigo B Mansur R Hamish McAllister-Williams James W Murrough Charles B Neme Source Type: research
Topical and Oral Roflumilast in Dermatology: A Narrative Review
Actas Dermosifiliogr. 2023 Sep 12:S0001-7310(23)00732-9. doi: 10.1016/j.ad.2023.09.005. Online ahead of print.ABSTRACTOral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. In dermatology, topical roflumilast is authorized by the US Food and Drug Administration for the treatment of plaque psoriasis and mild to moderate seborrheic dermatitis. Several studies have described the off-label use of roflumilast in dermatology, including a randomized controlled trial showing its usefulness in the treatment of psoriasis; case ...
Source: Actas Dermo-Sifiliograficas - September 14, 2023 Category: Dermatology Authors: M Mansilla Polo E Gimeno D Morgado Carrasco Source Type: research
Innovative Genoceuticals in Human Gene Therapy Solutions: Challenges and Safe Clinical Trials of Orphan Gene Therapy Products
Curr Gene Ther. 2023 Sep 11. doi: 10.2174/1566523223666230911120922. Online ahead of print.ABSTRACTThe success of gene therapy attempts is controversial and inconclusive. Currently, it is popular among the public, the scientific community, and manufacturers of Gene Therapy Medical Products. In the absence of any remedy or treatment options available for untreatable inborn metabolic orphan or genetic diseases, cancer, or brain diseases, gene therapy treatment by genoceuticals and T-cells for gene editing and recovery remains the preferred choice as the last hope. A new concept of "Genoceutical Gene Therapy" by using orphan ...
Source: Current Gene Therapy - September 13, 2023 Category: Genetics & Stem Cells Authors: Rakesh Sharma Source Type: research
Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review
This study describes published annualized asthma exacerbation rate (AAER) reductions from RCTs in patients with allergic severe asthma, overall and by baseline BEC category. A literature search was performed to identify published phase 3 RCT data of US Food and Drug Administration-approved biologics for severe asthma in patients with severe, uncontrolled asthma and confirmed sensitization to perennial aeroallergens. Analyses focused on AAER reduction versus placebo in the overall population and/or in those with an elevated or low BEC at baseline or screening. Baseline serum total immunoglobulin E levels varied between RCT ...
Source: Adv Data - September 12, 2023 Category: Epidemiology Authors: Jonathan A Bernstein Jean-Pierre Llanos Gillian Hunter Neil Martin Christopher S Ambrose Source Type: research
Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors: a systematic review and meta-analysis of 3 randomized controlled trials
Am J Cancer Res. 2023 Aug 15;13(8):3266-3274. eCollection 2023.ABSTRACTTrastuzumab deruxtecan (T-DXd, DS-8201) is a targeted antibody-drug conjugate that specifically targets human epidermal growth factor receptor 2 (HER2). In 2019, it was approved by the US Food and Drug Administration for the treatment of HER2-positive breast cancer. However, ongoing research is exploring its potential efficacy in other solid tumors, such as non-small-cell lung cancer and colorectal cancer, as well as in tumors with low HER2 levels. It is important to examine the safety and effectiveness of trastuzumab deruxtecan in these various types o...
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Ze-Lin Cai Hui-Ting Yang Ting Huang Zhuo-Ran Yu Ning Ren Jing-Yang Su Xian-Lei Lin He-Ran Zhou Source Type: research
Current Status of Robotic Gastrointestinal Surgery
This article reviews current trends and potential developments in robotic surgery.PMID:37690822 | DOI:10.1272/jnms.JNMS.2023_90-404
Source: Journal of Nippon Medical School - September 10, 2023 Category: Universities & Medical Training Authors: Keisuke Minamimura Keisuke Hara Satoshi Matsumoto Tomohiko Yasuda Hiroki Arai Daisuke Kakinuma Yukio Ohshiro Youichi Kawano Masanori Watanabe Hideyuki Suzuki Hiroshi Yoshida Source Type: research
